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Protein glycosylation regulates protein function and cellular
distribution. Additionally, aberrant protein glycosylations have
been recognized to play major roles in human disorders,
including neurodegenerative diseases. Glycoproteomics, a
branch of proteomics that catalogs and quantifies glycoproteins,
provides a powerful means to systematically profile the
glycopeptides or glycoproteins of a complex mixture that are
highly enriched in body fluids, and therefore, carry great
potential to be diagnostic and/or prognostic markers. Applica-
tion of this mass spectrometry-based technology to the study of
neurodegenerative disorders (e.g., Alzheimer’s disease and
Parkinson’s disease) is relatively new, and is expected to provide
insight into the biochemical pathogenesis of neurodegeneration,
as well as biomarker discovery. In this review, we have
summarized the current understanding of glycoproteins in
biology and neurodegenerative disease, and have discussed
existing proteomic technologies that are utilized to characterize
glycoproteins. Some of the ongoing studies, where glycoproteins
isolated from cerebrospinal fluid and human brain are being
characterized in Parkinson’s disease at different stages versus
controls, are presented, along with future applications of targeted
validation of brain specific glycoproteins in body fluids. # 2009
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I. INTRODUCTION
Advances in proteomic concepts and technologies, particularly
unbiased techniques, have stimulated a great interest in
application of mass spectrometry (MS) to explore neurodegener-
ative disorders, for example, Alzheimer’s disease (AD),
Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS)—one of the most important groups of diseases in our
rapidly aging population in developing and industrialized
countries (Chiang, Lam, & Luo, 2008). Application of these
techniques to neurodegenerative disorders is especially advanta-
geous because, despite decades of ‘‘mechanism’’- or ‘‘pathway’’
-based pursuits, the pathogenesis of most of these diseases
remains largely unknown (Cookson, 2005; Moore et al., 2005;
Thomas & Beal, 2007; Arakawa, Kita, & Niikura, 2008; Siddique
& Siddique, 2008). Indeed, in the past several years, proteomic
investigations that use different platforms with samples collected
from AD and PD patients have already revealed quite a few novel
proteins that are potentially critical, not only to the understanding
of the mechanisms of the diseases but also to new avenues to
diagnose these diseases and to monitor disease progression
(Castegna et al., 2002; Butterfield et al., 2003; Jin et al., 2006;
Finehout et al., 2007; Leverenz et al., 2007; Osorio et al., 2007;
Simonsen et al., 2007).
Defining protein biomarkers unique to a disease diagnosis or
progression in body fluids, particularly cerebrospinal fluid (CSF),
is currently one of the most exciting areas of research in
neurodegenerative disorders (Yuan & Desiderio, 2003, 2005;
Rite et al., 2007; Simonsen et al., 2007; Tumani et al., 2008; Yang
et al., 2008). CSF, which originates within the ventricles and
surrounds the brain and spinal cord, is an ideal source for
biomarker discovery for diseases of the central nervous system
(CNS) like AD and PD. The reasons include (Abdi et al., 2006;
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Zhang, 2007; Srivastava, Murphy, & Jeffery, 2008): (1) CSF is the
only body fluid that directly interchanges with the extracellular
fluid of the CNS, and therefore reflects pathological changes in
the CNS most directly, and (2) multiple CSF taps can be obtained
with minimal risk to make possible a longitudinal analysis of
biomarkers in a given cohort. That said, among thousands of
proteins identified by proteomics in human CSF thus far (Pan
et al., 2007b; Zougman et al., 2008), only a small portion are
related to the CNS structurally or functionally. This deficit in
identifying CNS-specific proteins is mainly due to the fact that
most of the CNS-specific proteins are low in abundance, and all
current proteomic techniques are biased towards abundant
proteins in a sample with a large dynamic range (Gulcicek
et al., 2005). One of the approaches to get around this difficulty is
to focus on a subproteome(s) that can be isolated readily (e.g.,
proteins with glycosylation, phosphorylation, or oxidation)
before proteomic profiling, thereby effectively reducing the
dynamic range of a given complex sample (Korolainen et al.,
2002; Bahl et al., 2008; Kubota et al., 2008). To this end,
characterizing glycoproteins is especially appealing because
they are intimately related to the health of cells, and in addition,
are relatively enriched in body fluids like CSF and plasma
(Ohtsubo & Marth, 2006).
In this report, we will begin by summarizing the current
understanding of glycoproteins in biology and neurodegenerative
disease, followed by an introduction of existing proteomic
technologies used to characterize glycoproteins. Next, we will
present some of the ongoing studies where glycoproteins isolated
from human CSF and brain tissue are characterized in PD at
different stages and in controls. Future applications of targeted
proteomics—to identify unique proteins in the CNS first,
followed by confirmation/validation of known proteins in CSF
or plasma—also will be addressed briefly.
II. GLYCOPROTEINS IN HEATH AND
NEURODEGENERATIVE DISEASE
A. Glycosylation in Health and Disease
Post-translational modifications (PTMs) play a key role to
modulate the activities and functions of most proteins in
biological systems (Hann, 2006). Among various PTMs,
glycosylation represents the most common and complicated
form. It is estimated that 50–60% of proteins in the human body
are modified by glycosylation (Apweiler, Hermjakob, & Sharon,
1999; Hagglund et al., 2004; Kameyama et al., 2006). A
glycoprotein often contains more than one oligosaccharide
attachment site, and each glycosylation site can be modified
with multiple oligosaccharide chains. Additionally, on a single
glycoprotein, the structure of oligosaccharides at each site can be
significantly different. Various glycosylated proteins are synthe-
sized mainly in the endoplasmic reticulum and Golgi via
reactions that involve sugar nucleotide synthases, transporters,
glycosyltransferases, glycosidases, and other sugar-modifying
enzymes. In addition, the structures of glycans can be easily
altered by changes of the physiological condition of the cells
(Lowe & Marth, 2003; Haltiwanger & Lowe, 2004). It should be
noted that, although it is beyond a review focused on
glycoproteins, a mass spectrometric study of glycans is itself
an active area of current research (Morelle & Michalski, 2005;
Zaia, 2008).
The amino acids known to be involved in glycosylation are
asparagine, arginine, serine, threonine, proline, hydroxyproline,
tryptophan, and tyrosine (Spiro, 2002). Typically, protein
glycosylation is categorized as either O-linked or N-linked.
The N-linked glycosylation, characterized by the attachment of
the glycan to an asparagine side chain of the protein, is by far the
most common (Nalivaeva & Turner, 2001). The consensus
sequence for N-glycosylation is Asn-Xaa-Ser/Thr, where Xaa is
any amino acid other than proline (Johansen, Marshall, &
Neuberger, 1961). The asparagine is linked to N-acetylglucos-
amine (GlcNAc) residues. Additional sugar residues in the
glycan depend on whether the glycosylation is the high-mannose
hybrid or complex type (Suzuki et al., 1995). In O-linked
glycosylation, on the other hand, the glycan is attached to the
serine/threonine side chain (Spiro, 1973). O-linked glycosylation
usually starts with an N-acetylgalactosamine (GalNAc) linked
to serine/threonine and, unlike N-linked glycosylation, no
consensus sequence that defines an O-linked glycosylation site
exists (Spiro, 1964, 1973, 2002; Tanaka, Bertolini, & Pigman,
1964). This type of glycosylation is observed most abundantly
in mucin-like glycoproteins that form part of epithelial
secretions in, for example, the gut, cervix, and lungs (Gendler
& Spicer, 1995; Hanisch, 2001). Another variation of O-linked
glycans is the Ser/Thr-O-GlcNAc sequence, which is abundant in
nucleocytosolic proteins that aid in signal transduction (Spiro,
2002).
One of the initial functions of glycosylation of a given
protein is to direct the protein to the appropriate subcellular
location; for example, many lysosomal proteins contain a
mannose-6-phosphate moiety, a signaling molecule for lysosome
(Kaplan, Achord, & Sly, 1977; Varki & Kornfeld, 1980).
Additionally, glycosylation has been implicated in numerous
biological processes, including cell growth and developmental
biology, immune response, tumor growth, metastasis, anti-
coagulation, cell-to-cell communication, and microbial patho-
genesis (Liu et al., 2002; Sasisekharan et al., 2002; Hwang et al.,
2003; Inatani et al., 2003; Lowe & Marth, 2003; Casu, Guerrini,
& Torri, 2004; Collins & Paulson, 2004; Guo et al., 2004; Lin,
2004; Dube & Bertozzi, 2005; Kinjo et al., 2005; Miller, Ernst, &
Bader, 2005). Aberrant protein glycosylations could also
contribute to human disorders, including neurodegenerative
diseases (Liu et al., 2002; Saez-Valero et al., 2003).
B. Glycosylation Alterations in Human
Neurodegenerative Disorders
Alterations in protein glycosylation have been related to human
neurodegenerative disease states, such as Creutzfeldt-Jakob
disease (CJD), AD, and PD (Saez-Valero et al., 2003; Silveyra
et al., 2006). Although the structural elucidation of glycoproteins
is a challenge because of their inherent complexity and
heterogeneity in biological systems, advances have been made
to identify a few proteins where glycosylation appears to be
important in the disease processes of AD and PD (Sihlbom et al.,
& HWANG ET AL.
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2004). A few key proteins involved in AD and PD pathogenesis
are discussed below.
Acetylcholinesterase (AChE), one of the critical enzymes
targeted in the current clinical management of AD, hydrolyzes
the neurotransmitter acetylcholine at cholinergic synapses, and is
widely distributed in brain regions. The glycosylation of AChE is
altered in the post-mortem brain and CSF of AD patients (Saez-
Valero et al., 1999, 2000). Additionally, the change in
glycosylation of AChE appears to be specific for AD because it
is not seen in other neurological diseases. More recently, the
glycosylation of a related enzyme, butyrylcholinesterase
(BuChE), also appears to be altered in AD CSF (Saez-Valero &
Small, 2001). Unfortunately, the sensitivity of diagnosing AD
with AChE and BuChE in the CSF is lower than that
considered necessary for a satisfactory biomarker (Saez-Valero
et al., 2003).
Microtubule-associated protein (MAP) tau, another essen-
tial protein involved in AD pathogenesis and related tauopathies,
undergoes several PTMs, and aggregates into paired helical
filaments. Known modifications of tau include hyperphosphor-
ylation, glycosylation, ubiquitination, glycation, polyamination,
nitration, and proteolysis. Glycosylation of tau is an early
abnormality that might facilitate the hyperphosphorylation of
tau, a pathological hallmark, in an AD brain (Liu et al., 2002).
Robertson, Moya, and Breen (2004) observed a significant
decrease in the glycosylated tau (O-linked) in AD post-mortem
brain samples compared with control; that decrease suggested an
inverse relationship between the two PTMs (i.e., glycosylation
vs. hyperphosphorylation). Furthermore, cells transfected with
the cDNA coding for O-GlcNAc transferase displayed altered tau
phosphorylation patterns as compared with control cells; these
alterations again suggested that changes in tau glycosylation
might influence its phosphorylation state. However, glycosyla-
tion of tau as a biomarker for AD has not been reported.
Until recently, very little has been known about the role of
glycosylated proteins in PD. Farrer et al. (2001) noted a potential
connection between the dysfunction of parkin, an E3 ubiquitin
ligase involved in the ubiquitination of protein substrates that
targets them for degradation by the proteasomal complex, and the
formation of a-synuclein inclusions. It turned out that the
mechanism that underlies this process could be the parkin-
mediated ubiquitination of an O-linked glycosylated form of a-
synuclein (Shimura et al., 2001). It should be emphasized that
mutations of parkin and a-synuclein result in the development of
autosomal recessive and dominant familial PD, respectively (Tan
& Skipper, 2007; Wakabayashi et al., 2007), and that changes in
the total amount of a-synuclein in CSF have been tested as
potential biomarkers of PD (also see later discussion).
From what has been discussed above, it is obvious that
glycosylation and glycoproteins play critical roles not only in
normal physiological conditions but perhaps also in neuro-
degenerative disorders like in AD and PD. On the other hand,
aside from two earlier reports of CSF glycoproteins (Sihlbom
et al., 2004; Pan et al., 2006), there is no systematic analysis of
glycoproteins in human tissue or CSF for any disease or even in
control subjects. Thus, in this report, we will present the
glycoproteins identified in human brain in addition to CSF after
an introduction of the current proteomic techniques used for
characterization of glycoproteins.
III. CHARACTERIZATION OF GLYCOPROTEINS BY
MASS SPECTROMETRY-BASED PROTEOMICS
A. Enrichment of Glycoproteins
As discussed above, the glycoproteome represents one of the
most important sub-proteomes in tissues and body fluids.
However, many glycoproteins might be low in abundance in
their glycosylated forms, even though the parent proteins are
abundant in CSF or plasma. Consequently, numerous attempts
have been made to develop methods to enrich glycoproteins
present in complex biological samples prior to mass spectro-
metric analysis.
1. Enrichment by Lectin Column
Lectins are widely distributed in nature and can recognize
carbohydrates on the surface of proteins. To isolate glycoproteins
or glycopeptides by affinity chromatography, various lectins can
be used (Cummings & Kornfeld, 1982; Hirabayashi, 2004).
Concanavalin A (ConA) is a lectin that binds mannosyl and
glucosyl residues that contain unmodified hydroxyl groups at
positions C3, C4, and C6, and can be utilized for the targeted
binding of certain oligosaccharide structures of N-glycosylated
proteins (Goldstein, Hollerman, & Smith, 1965; Yahara &
Edelman, 1972; Kamra & Gupta, 1987). The use of wheat germ
agglutinin (WGA) isolates glycostructures with N-acetylglucos-
amine and sialic acids (Nagata & Burger, 1974). Arachis
hypogaea agglutinin (PNA) is specific to glycans that contain
b-Gal, whereas Datura stramonium agglutinin (DSA) is specific
to glycans that contain GlcNAc residues (Novogrodsky et al.,
1975; Yamashita et al., 1987). Due to their ability to specifically
recognize distinct oligosaccharide epitopes (Sharon & Lis,
1989), lectins bound to appropriate matrices like agarose,
membranes, or magnetic beads, can be used to isolate, frac-
tionate, and characterize glycoproteins on the basis of their
different glycan structures (Wiener & van Hoek, 1996; Bundy &
Fenselau, 2001). In this regard, affinity chromatography with
lectins is a useful and powerful technique to fractionate and
isolate glycans and glycopeptides. The combination of lectin
chromatography and MS analysis provides high-sensitive
detection and useful information on glycan structures, and
enables further biological approaches. However, because indi-
vidual lectins display unique binding specificities, separation
with a particular lectin will isolate only a fraction of
glycoproteins or glycopeptides that bind to that lectin with high
affinity (Xiong, Andrews, & Regnier, 2003; Bunkenborg et al.,
2004; Ghosh et al., 2004). To overcome the limitation of selective
capture of a subset of glycoproteins for a given lectin, a technique
has been introduced for glycoprotein/peptide isolation and
enrichment from complex mixtures that involves double lectin
chromatography prior to identification with liquid chromato-
graph (LC)-electrospray ionization (ESI) MS (Bunkenborg et al.,
2004). Recently, a more elegant method has been established
with a multi-lectin column, which allows for an almost complete
enrichment of glycoproteins from biological fluids (Yang &
Hancock, 2004; Wang, Wu, & Hancock, 2006). In a similar
manner, lectin arrays have been developed that contain more than
35 different lectins that allow a qualitative and quantitative
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profiling of glycoprotein glycan patterns in a rapid and sensitive
high-throughput manner (Kuno et al., 2005). Finally, lectin
microcolumns have also been generated that are applicable to
high-pressure analytical schemes, and thus, can be directly
coupled on-line to ESI-MS to enable a highly sensitive semi-
automated profiling of glycoproteins (Madera, Mechref, &
Novotny, 2005; Madera et al., 2006, 2007).
2. Enrichment with Hydrazide
Hydrazide chemistry has been used to selectively isolate,
identify, and quantify N-linked glycopeptides in a much more
specific and efficient manner (Zhang et al., 2003). This method is
based on the conjugation of glycoproteins to a solid support with
hydrazide chemistry after periodate-mediated oxidation of the
carbohydrate. Peptide moieties of the covalently captured
glycopeptides are released with PNGase F treatment to allow
the peptide and glycosylation site to be identified. Recently, Sun
et al. (2007) reported a novel chemical capture approach that
focuses on a more efficient glycopeptide enrichment. In this
approach, glycopeptides derived from glycoproteins are enriched
by selective capture onto a solid support with hydrazide
chemistry followed by enzymatic release of the peptides and
subsequent analysis by tandem MS. Digestion of proteins into
peptides improves the solubility of large membrane proteins, and
exposes all of the glycosylation sites (at least in theory) to ensure
an equal accessibility to external capture reagents. Notably,
whereas the specificity has been increased by capturing N-linked
glycopeptides/glycoproteins with the hydrazide chemistry, this
method is restricted to N-glycopeptides and, in addition,
information on the carbohydrate structures is lost due to the
destruction and removal of the glycan moieties.
3. Other Methods for Enriching Glycoproteins
Besides lectins and hydrazide, a few other techniques, including
treatment with boronic acids, have also been employed to
facilitate enrichment of glycoproteins. Because boronic acids
enhance the capture of the more heterogeneous group of O-linked
oligosaccharides, this method has been incorporated into lectin
methodology; for example, a boronic acid-lectin affinity
chromatography column has been used to isolate glycoproteins
with selective and/or combined elution (Monzo, Bonn, &
Guttman, 2007).
B. Mass Spectrometric Analysis of Glycoproteins/
Peptides
Modern MS has greatly facilitated the characterization of
glycoproteins because it provides glycosylation site-specific
information by conducting glycopeptide-based analysis, wherein
the glycan and its attachment site to the protein can be elucidated
in the same experiment; at least in theory. This glycosylation site-
specific information is useful to elucidate functional properties of
the glycoprotein. Typically, glycopeptide-based MS analysis
entails an enzymatic cleavage of glycoproteins with an
endoprotease, followed by a separation technique and mass
analysis.
1. Desalting
When analyzing glycopeptides and glycoproteins, it is necessary
to desalt the sample and remove organic contaminants to avoid
the formation of salt adducts, thereby obtaining more-informa-
tive MS spectra. Cation and anion exchange materials have been
used commonly for desalting (Lattard et al., 2006). One of the
efficient methods is to use a microcolumn in a GELoader tip
(Eppendorf) into which a mixed bed resin column of AG-3 (to
remove anions), AG-50 (to remove cations), and C18 (to remove
organic materials) are packed (Kussmann et al., 1997). Hydro-
philic interaction liquid chromatography (HILIC) (Hagglund
et al., 2004) and graphite columns (Larsen, Cordwell, &
Roepstorff, 2002) are also useful for desalting.
2. Identification of Glycoproteins by Mass Spectrometric
Technologies
Most of the large-scale glycoprotein identification studies have
used a shotgun proteomics approach, in which glycoproteins are
typically trypsin-digested and de-glycosylated so that glycosy-
lated peptides can be sequenced in their deglycosylated forms
with MS/MS. For glycopeptides with N-linked glycosylation
site(s), most of the glycans can be removed with PNGase F. The
enzyme cleavage of a glycan group converts asparagine to
aspartic acid in a peptide, to introduce a mass difference of 0.984
Da and a negative charge. This phenomenon was used to map the
N-linked glycosylation site(s) using MS (Zhou, Aebersold, &
Zhang, 2007). In the past few years, several studies have used MS
to profile N-linked glycoproteins in human body fluids. Liu et al.
(2005) applied immunoaffinity subtraction and hydrazide
chemistry to enrich glycoproteins from human plasma. The
captured plasma glycoproteins were subjected to two-dimen-
sional (2D) LC separation (strong cation exchange [SCX] and
reverse-phase capillary LC) followed by tandem MS or MS/MS
analysis with a Fourier transform ion cyclotron resonance mass
spectrometer. A detection sensitivity at low ng/mL was achieved.
A total of 2,053 different N-glycopeptides, representing 303 non-
redundant glycoproteins, were identified, including many low-
abundance glycoproteins. Other studies applied a lectin affinity-
based approach to characterize serum and plasma N-linked
glycoproteins, and have added significant numbers of glyco-
proteins to the blood glycoproteome database (Zhang et al., 2003;
Yang & Hancock, 2004). Related to the study of neurodegener-
ative diseases, the CSF glycoproteome has been investigated in
an experiment, where lectin affinity and hydrazide chemistry
enrichment methods were both applied to reveal 216 glycopro-
teins (Pan et al., 2006).
Different approaches have characterized O-glycosylation
with tandem mass spectrometry. A very sensitive technique to
identify O-glycosylated sites employs the use of ammonia or
ethylamine for the specific release of O-linked glycan chains. The
integrity of the peptide backbone was retained and ammonia or
ethylamine was incorporated into the amino acid residue(s) to
& HWANG ET AL.
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which the glycan(s) had been attached. Thus, the former
glycosylation site was labeled, and thus, can be identified by
the mass alteration of 1 Da and þ27 Da for ammonia and
ethylamine, respectively (Rademaker et al., 1998; Hanisch,
Jovanovic, & Peter-Katalinic, 2001). The limitations of collision-
induced dissociation (CID) ESI-MS/MS for glycosylation site
analysis (i.e., the dominating fragmentation of the glycan chains)
can be overcome with different tandem MS techniques. Haynes
and Aebersold (2000) demonstrated a technique that provided
simultaneous detection and identification of O-GlcNAc-modified
peptides with low-energy collisions in tandem MS. The differ-
ential between the energy required to remove the O-GlcNAc
group versus the energy required to fragment the peptide chain
allows the O-GlcNAc group to be detected and the peptide
sequence, and therefore the protein, to be identified. More
recently, ‘‘soft’’ collision techniques, such as electron capture
dissociation (ECD) and electron transfer dissociation (ETD)
(Mormann, Paulsen, & Peter-Katalinic, 2005; Catalina et al.,
2007), have led to a preferential cleavage of the peptide backbone
and to leaving glycan structures intact, to thus allow an
unambiguous assignment of the glycosylation site in N- and O-
glycopeptides (Hakansson et al., 2001; Hogan et al., 2005). To
enhance the specificity of O-glycosylation analysis, Durham
et al. applied a serial lectin affinity chromatography that combine
ConA and Jacalin to enhance the identification of O-glycosylated
sites on proteins from the human blood proteome (Durham &
Regnier, 2006). The enriched O-glycopeptides were deglycosy-
lated with oxidative elimination and analyzed with ESI and
MALDI (matrix-assisted laser desorption/ionization) tandem
MS to identify over thirty O-glycosylated glycoproteins from
human serum.
MALDI-based mass spectrometric analysis usually produ-
ces singly charged glycopeptide ions that can be analyzed off-line
with high sensitivity after deposition of nano-LC-derived
glycopeptide fractions onto the MALDI-target (Lochnit &
Geyer, 2004). This technique is complementary to ESI
technology, because ESI mass spectra are sometimes too
complicated to fully assign oligosaccharide structures due to
the formation of many multiply charged ions. With a MALDI-
TOF/TOF-instrument, glycopeptides can be further analyzed via
characteristic fragment ions that can sequence the glycan and the
peptide simultaneously (Krokhin et al., 2004; Kurogochi &
Nishimura, 2004; Stephens et al., 2004; Wuhrer, Hokke, &
Deelder, 2004). Nonetheless, a more systematic assessment of
O- or N-glycosylation sites on glycoproteins might require the
use of mass spectrometers with higher mass accuracies; for
example, ESI or MALDI with Fourier transform ion cyclotron
resonance mass spectrometry (FT-ICR) (Irungu et al., 2008). FT-
ICR MS provides the high mass accuracy needed to improve the
specificity for protein database search results, and enhances the
prediction of glycoforms. Sihlbom’s group applied FT-ICR MS
and infrared multi-photon dissociation (IRMPD) to determine
the glycosylation states of isoforms of CSF proteins from
individual AD patients compared to controls (Sihlbom et al.,
2004). In that study, they reported that the sub-femtomole
sensitivities of FT-ICR MS analyzed 2D gel-separated complex
human protein mixtures. An additional advantage to IRMPD is
that it selectively dissociates the glycosidic bonds of N-linked
glycans (amino acid consensus sequence N–X–S/T/C, in which
X cannot be P).
3. Isotope Labeling for Quantification of Glycoproteins
Characterizing glycoproteins as extensively as possible is just the
first step to define biomarkers unique to a disease or disease
progression. A more important process is to quantify the changes
associated with a disease or a disease stage. Additionally,
quantitative glycoproteomics can help to characterize the
regulatory pathways and complex system networks by providing
protein concentration information that corresponds to different
cellular states. Although label-free techniques have been
developed by numerous investigators (Levin et al., 2007), most
published studies with human samples largely rely on various
isotope-labeling techniques for quantification, particularly when
large-scale profiling is the main focus. Examples include the use
of chemical reactions to introduce isotopic tags at specific
functional groups on peptides or proteins, such as ICAT (isotope-
coded affinity tags) (Gygi et al., 1999; Haqqani, Kelly, &
Stanimirovic, 2008) and iTRAQ (isobaric tags for relative and
absolute quantitation) (Aggarwal, Choe, & Lee, 2006) as well as
the methods that introduce stable-isotope tags via enzymatic
reaction, such as enzymatic 18O incorporation (Kaji et al., 2003,
2006; Zhang et al., 2003).
ICAT labels the side chains of cysteinyl residues in two
reduced protein samples with the isotopic light or heavy reagent,
respectively, and generates the mass signatures that identify
sample origin and serve as the basis for accurate quantification, to
thus afford simultaneous comparison of two proteomes. How-
ever, ICAT selectively targets cysteine residues, and therefore
approximately 3% of mammalian proteins that lack cysteine
residues cannot be analyzed (Colangelo & Williams, 2006). In
addition, some cysteines are blocked or are inaccessible to the
labeling reagent. More recently, iTRAQ technology, which labels
lysines and N-termini, has been used for quantitative proteomics
in human body fluid and tissue (Martin et al., 2008; Song et al.,
2008). The iTRAQ technology has a significant advantage over
other methods due to its capability to multiplex up to eight
samples in a single experiment (D’Ascenzo, Choe, & Lee, 2008).
Another positive aspect includes unbiased peptide labeling,
because iTRAQ isobaric tags theoretically label lysine side
groups and all free amino-terminal groups of the peptides present
in a sample. The iTRAQ tags consist of a reporter group, a
balance group, and a peptide reactive group that covalently binds
to the peptides. The tandem mass spectra include contributions
from each sample, and the individual contributions of each
sample can be measured by the intensity of the reporter ion peaks.
Moreover, a chemical approach for the N-glycosylation identi-
fication (i.e., hydrazide chemistry capture) can be incorporated
with the iTRAQ quantification method because an iTRAQ-
labeled peptide is chemically stable in other buffer systems.
Notably, in addition to quantification, isotope-labeling
methods might also increase the certainty of glycoproteome
assignments and enable quantitative comparisons of glycosylated
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samples. For example, several groups have used isotope-coded
glycosylation-site-specific tagging (IGOT) for the large-scale
identification of N-glycosylated proteins from a complex
biological sample (Kaji et al., 2003, 2006). The IGOT approach
is based on the lectin column-mediated affinity capture of a set of
glycopeptides generated by tryptic digestion of protein mixtures,
followed by peptide-N-glycosidase-mediated incorporation of a
stable isotope tag, 18O, specifically into the N-glycosylation site.
The 18O-tagged peptides are identified with multi-dimensional
LC-MS-based technology. The application of this method to
characterize N-linked high-mannose and/or hybrid-type glyco-
proteins from an extract of Caenorhabditis elegans proteins
identified 250 glycoproteins, including 83 putative transmem-
brane proteins, with the simultaneous determination of 400
unique N-glycosylation sites. A similar approach was later used
to identify and quantify N-linked glycoproteins in serum (Zhang
et al., 2003). In this study, the N-linked glycopeptides were
oxidized and captured directly on a hydrazide column; the
quantitation was achieved by comparing two samples that were
tagged differentially with 18O- or 16O-labeled water.
IV. CHARACTERIZATION OF GLYCOPROTEINS
ASSOCIATED WITH PARKINSON’S DISEASE AND
DISEASE PROGRESSION
In the next few sections, we will use one of the ongoing projects
focused on PD to illustrate a strategy that identifies and quantifies
CNS-specific glycoproteins at the same time. However, only
identification data will be shown in this report.
A. Parkinson’s Disease and Its Progression
PD is traditionally considered a movement disorder that results
from a relatively selective loss of neurons in the brainstem,
including dopaminergic (DAergic) neurons in the substantia
nigra pars compacta (SNpc), with subsequent loss of striatal
dopamine and accompanied by the formation of intraneuronal
inclusions called Lewy bodies that contain a-synuclein as one of
the major proteins (Lowe, Graham, & Leigh, 1997; Jankovic,
2001). More recently, however, it has become increasingly clear
that neurodegeneration in PD is widespread with associated
presentation of multiple ‘‘non-motor’’ symptoms, including
cognitive impairment, particularly as the disease advances.
Cognitive impairment in PD, ranging from mild dysfunction to
severe dementia, has major clinical consequences, because it has
been associated with a reduced quality of life (Schrag,
Jahanshahi, & Quinn, 2000), shortened survival (Nussbaum
et al., 1998), and increased caregiver distress compared to PD
without cognitive impairment (Aarsland et al., 1999). It should be
emphasized that the risk of developing dementia in PD patients is
several-fold higher than for community-dwelling controls
(Marder et al., 1995; Aarsland et al., 2001, 2003). Furthermore,
in more recent studies, when PD patients are tested more
rigorously, it has been estimated that 36% of patients newly
diagnosed with PD had mild cognitive impairment (MCI)—a
prodrome of PD dementia (Foltynie et al., 2004; Levin & Katzen,
2005), and that 57% of patients with newly diagnosed PD will
develop MCI within 3–5 years (Williams-Gray et al., 2007).
Numerous clinicopathological studies have sought to
identify the structural basis of cognitive impairment in patients
with PD dementia (PDD). Though remaining to be investigated, it
appears that, in a significant portion of PD patients, PD
progression is characterized pathologically by the spreading of
aggregateda-synuclein deposits from the brainstem to other parts
of the brain (Braak et al., 2002, 2003). A staging procedure for the
PD-related inclusion body pathology (i.e., Lewy neurites and
Lewy bodies) in the brain proposes that the pathological process
begins at two sites (the medulla oblongata and olfactory bulb) and
progresses in a topographically predictable sequence in six
stages. During stages 1–2, the inclusion body pathology remains
confined to the medulla oblongata, pontine tegmentum, and
anterior olfactory structures. In stages 3–4, the basal midbrain,
including SNpc, and forebrain become the foci of the pathology,
and the illness reaches its symptomatic phase (motor symptoms).
In the final stages 5–6, the pathological process is seen in the
association areas and primary fields of the neocortex. The basic
concept is diagramed in Figure 1.
B. Biomarkers for Parkinson’s Disease and
Parkinson’s Disease Progression
Two approaches, protein-specific, for example, a-synuclein
(Jakowec et al., 1998; Borghi et al., 2000; Verbeek, De Jong, &
Kremer, 2003; El-Agnaf et al., 2006; Tokuda et al., 2006) and DJ-
1 (Waragai et al., 2006; Hirotani et al., 2008), and unbiased
profiling (Abdi et al., 2006) have been undertaken to define
protein biomarkers unique to PD diagnosis. Profiling is advanta-
geous because it provides an unbiased view of a disease or stage
of a disease whose pathogenesis is largely unknown. In addition,
multiple markers can be generated for a given disease when a
profiling approach is taken, and generally speaking, a combina-
tion of multiple markers offers better sensitivity and specificity
than a single protein alone for disease diagnosis (Zhang et al.,
2008). There are no known markers that can predict PD
progression, whether related to motor symptoms or cognitive
impairment; that concept has been emphasized more recently. To
resolve this issue, in the last few years, with unbiased proteomics,
we have compared the proteome of brain tissue associated with
Lewy body progression as PD advances, with the goal of
identifying proteins before Lewy body formation in the neo-
cortex (Fig. 1). However, in an earlier analysis, among 1,500
proteins identified in CSF only 9% were present in the proteins
identified in human brain tissue (Pan et al., 2007a,b). It has been
hypothesized that there are at least two limitations associated
with the previous approaches: (1) the cellular fractionation
technique is biased against extracellular proteins, because most
of them are discarded along with cell debris (Jin et al., 2006; Pan
et al., 2007a), and (2) the large dynamic range of the CSF
proteome makes it very challenging to identify proteins of low
abundance [albumin and immunoglobulins constitute more than
75% of CSF proteins (Srivastava, Murphy, & Jeffery, 2008)].
Indeed, both limitations are the major problems that must be dealt
with not only in diseases related to the CNS but also in the
biomarker discovery field in general (Aebersold et al., 2005; Qian
& HWANG ET AL.
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et al., 2006). To increase the likelihood of identifying proteins
that are accessible clinically, most investigators have turned their
attention either to removing high-abundance proteins before
profiling or to a specific sub-proteome with a unique PTM; for
example, proteins with glycosylation. As mentioned earlier,
protein glycosylation, and in particular N-linked glycosylation, is
prevalent in proteins destined for extracellular environments
(Roth, 2002).
C. Glycoprotein/Peptide in Human Cerebrospinal
Fluid and Brain Tissue
1. Glycoproteins in Human Cerebrospinal Fluid
This investigation consisted of four groups: control subjects,
AD, and PD patients at two different stages. More specifically, the
control group consisted of 29 individuals aged 70 6 years, 18
men and 11 women, with no history, symptoms, or signs of
psychiatric or neurological disease. The AD group consisted of
51 patients aged 69 9 years, 28 men and 23 women, all of whom
underwent a comprehensive clinical examination, and were
diagnosed with AD according to NINCDS ADRDA criteria
(Jobst, Barnetson, & Shepstone, 1997). The early stage PD group
consisted of 11 patients aged 61 8 years, 9 men and 2 women,
all of whom underwent a comprehensive clinical examination
and were diagnosed with PD at a Hoehn and Yahr stage of 1.5 or
less. The late stage PD group consisted of 11 patients aged
66 7 years, 7 men and 4 women, all of whom underwent a
comprehensive clinical examination and were diagnosed with PD
at a Hoehn and Yahr stage of 3 or greater. All CSF samples have
been controlled for blood contamination before pooling samples
into four groups (Abdi et al., 2006). The pooled CSF samples
were mixed with a protease inhibitor cocktail, and stored at
808C before use. To perform quantitative analysis of glyco-
proteins unique to PD and PD progression, samples were digested
with trypsin, followed with iTRAQ labeling, before hydrazide
bead capture. Of note, quantitative data are still being evaluated
currently and will be published separately at a later time. The
glycopeptides derived from glycoproteins in human CSF were
FIGURE 1. Cognitive impairment associated with PD progression is characterized pathologically by the
spreading of a-synuclein aggregates, the main component of Lewy bodies, from brainstem to limbic system
and eventually to the neocortex (Braak et al., 2003). The boxed area, the middle frontal gyrus, is the tissue
source for a recent non-biased profiling (Pan et al., 2007a; Shi et al., 2008) as well as characterization of
glycoproteins to reveal proteins unique to PD and/or PD progression, particularly development of dementia.
[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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enriched by hydrazide bead capture followed by enzymatic
release of the N-linked glycosylated peptides. Peptides from each
sample were dissolved in 0.5% trifluoroacetic acid (TFA), and
separated with reverse phase (RP) chromatography. MS/MS
analysis used the 4800 Proteomics Analyzer with TOF/TOF
OpticsTM (Applied Biosystems, Foster City, CA, USA). The MS/
MS spectra were extracted and searched against the Inter-
national Protein Index (IPI) human protein database (version
3.42 from the European Bioinformatics Institute [EBI]) with
ProteinPilotTM software (version 2.0.1, revision 33087, Applied
Biosystems) with the ParagonTM method. The raw peptide
identification results from the ParagonTM Algorithm (Applied
Biosystems) searches were further processed with the
Pro GroupTM Algorithm (Applied Biosystems) within the
ProteinPilotTM software before final display. The Pro Group
Algorithm uses the peptide identification results to determine
the minimal set of proteins that can be reported for a given protein
confidence threshold. For each protein, Pro Group Algorithm
reports two types of scores for each protein: unused ProtScore
and total ProtScore. The total ProtScore is a measurement of all
the peptide evidence for a protein, and is analogous to protein
scores reported by other protein identification software. The
unused ProtScore, however, is a measurement of all the peptide
evidence for a protein that is not better explained by a higher
ranking protein. In other words, the unused ProtScore is
calculated with the unique peptides (peptides that are not
used by the higher ranking protein), and it is a clearer indicator
of protein evidence and assists in singling out members of a
multiprotein family. All reported data were based on
95% confidence for protein identification as determined by
ProteinPilot (ProtScore 1.3). Identified glycoproteins were
checked against the UniProtKB/Swiss-Prot database and the
Institute for Systems Biology (ISB) database as glycoproteins
with known glycosylation sites or probable/potential glycosyla-
tion sites.
The MALDI-TOF-TOF analysis revealed a total of 283 non-
redundant glycoproteins in human CSF (Appendix I). In
comparison with the existing publicly accessible database, 243
of these proteins were annotated in UniProtKB/Swiss-Prot and
the ISB database as glycoproteins with known glycosylation sites
or probable/potential glycosylation sites. The specificity of this
approach was approximately 86% (243/283). When this dataset
is compared with what has been published earlier, where lectin
affinity purification and hydrazide chemistry were both used to
characterize CSF glycoproteins with an ion trap mass spectrom-
eter (LCQ) (Pan et al., 2006), 87 were observed in both datasets;
that is, a 36% overlap of 243 glycoproteins. This overlap is
considered reasonable, given that a different database and
different technology (LCQ vs. MALDI-TOF-TOF as well as
hydrazide chemistryþ lectin affinity vs. hydrazide chemistry
alone) were used to characterize glycoproteins in two different
studies.
2. Glycoproteins in Brain Tissue
An alternative approach to increase the chances to identify
proteins of low abundance is to perform targeted proteomics; that
is, identify proteins unique to a disease or disease progression in
tissue, followed by confirmation and validation in a body fluid.
This concept will be discussed further in a later section (targeted
proteomics). To characterize tissue glycoproteins associated with
PD and PD progression, particularly those related to development
of PD dementia, the advantage of well-characterized PD brains
obtained at autopsy was taken. In this study, all PD cases had been
given a clinical diagnosis of PD initially, which meant that
dementia with Lewy body disease (DLB) cases, a disease
overlapping with PD with dementia (PDD) cases pathologically,
were excluded from the study. The brain region of interest was the
middle frontal gyrus (Fig. 1), and the four groups of cases (five
per group with matching age, gender, and post-mortem interval)
were investigated: normal age-matched control (78.6 4.0;
male/female [M/F] ratio¼ 3:2), PD with brainstem Lewy bodies
only (77.2 11.3; M/F¼ 3:2), PD with brainstem and limbic
Lewy bodies (78.8 8.3; M/F¼ 3:2), and PD with Lewy bodies
in neocortex plus brainstem and limbic system (77.0 1.9; M/
F¼ 3:2). Glycoproteins were isolated with methods identical to
those described for CSF above after iTRAQ labeling. Again, the
quantitative data will be published in a separate manuscript that is
under preparation.
This investigation revealed 394 non-redundant glycopro-
teins (Appendix II). In comparison with the existing database,
343 of these proteins were annotated in the UniProtKB/Swiss-
Prot and ISB databases as glycoproteins with known glycosyla-
tion sites or probable/potential glycosylation sites. The specific-
ity was approximately 87% (343/394). It should be emphasized
that this dataset represents the first systematic analysis of
glycoproteins in human brain in normal and diseased settings.
3. Gene Ontology Analysis
Over the last few years, a Gene Ontology (GO) method has been
used to study datasets generated by proteomic analysis (Pan et al.,
2007a,b; Kitsou et al., 2008; Shi et al., 2008) to provide insight
into the underlying biology (Alexa, Rahnenfuhrer, & Lengauer,
2006). GO analysis, either based on cellular components (CC) or
biological processes (BP), detects over-represented GO catego-
ries (Alexa, Rahnenfuhrer, & Lengauer, 2006). When the
glycoproteins identified in human CSF and tissues were classified
by GO analysis, it was apparent that a majority of the proteins
belong to either the extracellular compartment or are associated
with the plasma membrane (Fig. 2). This is entirely consistent
with the claim that most membrane proteins are glycosylated, and
that a significant portion of glycoproteins are designated
for secretion into the extracellular fluid and thereby enter blood
or CSF (Yang et al., 2005).
4. A Brief Discussion of Overlapped Proteins
As indicated earlier, one of the major goals to isolate
glycoproteins is to reveal CNS-specific proteins that are low in
abundance in body fluids with the potential to serve as biomarkers
for disease diagnosis or disease progression. To this end, there are
a few features of the data presented above that must be stressed:
(1) isolation of glycoproteins significantly increased the portion
of proteins related to CNS function and/or structure (a partial list
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of those proteins is shown in Table 1), (2) the overlap between the
CSF and tissue proteomes is also improved significantly over the
general profiling, where only 140 proteins were found in tissue
and CSF general profiles that account for 9% of1,500 identified
CSF proteins. When glycoproteins were analyzed, 98 proteins
were seen in brain tissue (a total of 343 proteins) and CSF (a total
of 243 proteins) to account for 43% of CSF glycoproteins.
Furthermore, several of the overlapping proteins identified with
glycoprotein isolation are likely related to PD pathogenesis. For
example, ceruloplasmin and transferrin, both regulate iron
metabolism, were reported to be dysregulated in PD patients
(Dexter et al., 1989; Riederer et al., 1989).
Besides the proteins known to be important to PD patho-
genesis, others such as neuroserpin, neural cell adhesion
molecule, and neuronal pentraxin II are critical to CNS function,
and some have been linked to other neurodegenerative diseases.
For example, one of the overlapping proteins, neuroserpin, is a
member of the serpin family of serine protease inhibitors. Tissue-
distribution analysis reveals a predominantly neuronal expres-
sion during the late stages of neurogenesis and, in the adult brain,
FIGURE 2. GO analysis of glycoproteins identified in human brain (A) and CSF (B), to clearly emphasize
the fact that a majority of the proteins are distributed to extracellular and membrane compartments.
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TABLE 1. A partial list of overlapped glycoproteins between human CSF and brain tissue
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in areas where synaptic changes are associated with learning and
memory (synaptic plasticity). To this end, it should be mentioned
that synaptic dysfunction appears to be one of the major early
signs of PD progression in human cortex (Pisani et al., 2005).
Another example, neural cell adhesion molecule, is involved in
signal transduction (Niethammer et al., 2002), and promotes
neurite outgrowth and fasciculation (Rutishauser & Edelman,
1980). In the SNpc of PD patients, polysialated-neural
FIGURE 3. The illustration of mass spectrometry-based targeted quantitative analysis to detect N-linked
glycopeptides in body fluids. Synthetic peptides with stable isotope labeling are used as internal standards
for the quantification of endogenous glycopeptides. As an example, N-linked glycopeptide
AQLLQGLGFN*L#TER (Corticosteroid-binding globulin) was extracted from human serum with
hydrazide chemistry-based solid-phase extraction and detected with an LC MALDI TOF/TOF platform
with targeted approach. (Note: # indicates the amino acid that was stable isotope labeled (13C and 15N) in
reference peptides; * indicates enzyme-catalyzed conversion of asparagines to aspartic acid at the site of
carbohydrate attachment.) [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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cell-adhesion molecule-positive immature neurons were
detected. The polysialated neural cell adhesion molecule is a
marker of immature, migrating neuroblasts (Yoshimi et al.,
2005). The third example, neuronal pentraxin II, was recently
reported to be highly up-regulated in PD and is a novel
component of Lewy bodies (Moran et al., 2008). Neuronal
pentraxin II is also known as the neuronal activity-regulated
protein, which is secreted and involved in long-term neuronal
plasticity (Hsu & Perin, 1995).
V. FUTURE PERSPECTIVES
From the analysis of glycoproteins of human CSF and brain
tissue, it is obvious that even a focused analysis of glycoproteins
remains inadequate for an extensive characterization of CNS-
specific proteins. When comparing glycoproteins identified in
brain tissue (Appendix II) with those identified in CSF (Appendix
I), we found, as expected, that proteins related to the CNS
structurally and/or functionally are more frequently identified/
quantified in tissue. Because of dynamic issues and a common
technical caveat associated with MS-based proteomics, absence
of a protein only means that it is not detected, but not necessarily
absent, in a particular analysis. We believe that it is critical to
examine the tissue proteins unique to a disease process (PD
diagnosis and progression in this case) in body fluid by targeted
analysis. In our opinion, this approach is critical to the CNS-
based disease, given that the CNS is highly organized and
specialized with each neurodegenerative disorder that involves
selective brain regions. For example, AD predominantly affects
the cerebral cortex and hippocampus, whereas PD usually
damages brainstem structures, particularly during the early
stages of the diseases before other brain regions are involved
(Braak et al., 2000; Wenk, 2003; Sudo et al., 2005). Therefore, the
pathology-specific proteins could be so diluted in CSF that they
are difficult to detect even when glycoproteins are isolated first.
Targeted analysis of proteomics—first identify unique
proteins in the CNS, followed by confirmation/validation of
known proteins in CSF or plasma in this case—indicates a
progression away from unbiased profiling toward a multi-phase
technology that allows key elements that uniquely represent a
specific biological condition to be analyzed (Aebersold, 2003;
Pan et al., 2005). The technology uses isotope dilution followed
by MS analysis (Gerber et al., 2003; Anderson et al., 2004;
Anderson, 2005; Pan et al., 2005; Anderson & Hunter, 2006), in
which test-samples are supplemented (spiked) with synthetic
peptides that serve as the signature markers to identify and
quantify native peptides (target) within each sample. To date, few
investigations have been reported that use the concept of
candidate-based targeted quantitative proteomics to study
selected peptides/proteins for biomarker verification/validation
via ESI or MALDI based platforms. For the ESI approach, a
hybrid triple-quadrupole/ion trap mass spectrometer was used to
identify and quantify a selected group of targeted proteins within
human plasma (Anderson & Hunter, 2006). Alternatively, an
off-line LC MALDI-TOF/TOF platform was established to
monitor a panel of targeted glycopeptides/glycoproteins in
human serum, in conjunction with a sample preparation strategy
that extracted deglycosylated N-linked glycopeptides from
human serum (Pan et al., 2005). These early investigations have
demonstrated the feasibility and advantages of the MS-based
targeted quantitative proteomics to simultaneously identify and
quantify a panel of selected peptides/proteins in a complex
milieu, and consequently could be applied for biomarker
verification/validation of AD and PD. Figure 3 demonstrates
the basic concepts and work flow to validate a protein of interest
in an LC-MALDI format. In fact, we have recently applied this
technology to confirm/validate a subset of proteins identified in a
previous non-biased proteomics profiling (Abdi et al., 2006)
unique to AD and PD, respectively, in CSF (Pan et al., 2008). A
project is also underway to use this platform to cross-examine the
proteins identified in brain tissue with CSF (and vice versa), and
eventually in human plasma.
VI. CONCLUDING REMARKS
The development of technologies from gel electrophoresis-
based approaches to high-resolution MS-based approaches for
protein identification and quantification has revolutionized
protein biomarker discovery critical to disease diagnosis and
disease progression monitoring, as well as greatly facilitated
studies to reveal the molecular events that underlie neuro-
degenerative diseases. Among these studies, protein glycosy-
lation and glycoproteomics are growing fields of interest due to
the relationship between glycosylation degree/type and the
health status of cells. The discovery and identification of
glycosylated peptides and proteins and the analyses of their
glyco-structures are increasingly important in diagnosis and
treatment of neurodegenerative diseases. However, it is obvious
that the complete characterization of glycoproteins remains a
major challenge in the years to come, largely because of the
enormous dynamic range of typical human samples as well as
the heterogeneity of human beings. Thus, effective and in-depth
protein identification of glycoproteins involved in neuro-
degenerative disorders requires a concerted approach, including
improved glycoprotein enrichment, extensive separation of
proteins/peptides, high-resolution tandem mass spectrometric
analysis, at profiling and targeted modes, and state-of-the-art
bioinformatics.
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